SCP
ESPR

Sivia Capital Partners’s Esperion Therapeutics ESPR Stock Holding History

Sivia Capital Partners’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-25,738
Closed -$70.5K – 566
2026
Q1 		$70.5K Sell
25,738
-12,191
-32% -$38.6K 0.01% 448
2025
Q4 		$140K Hold
37,929
– – 0.03% 537
2025
Q3 		$101K Buy
37,929
+12,191
+47% +$23.6K 0.03% 459
2025
Q2 		$25.3K Buy
+25,738
New +$25.8K 0.01% 433
2025
Q1 		– Sell
-20,000
Closed -$44K – 298
2024
Q4 		$44K Hold
20,000
– – 0.02% 202
2024
Q3 		$33K Hold
20,000
– – 0.02% 215
2024
Q2 		$44.4K Buy
+20,000
New +$47K 0.03% 191

Other funds holding ESPR

GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

Sivia Capital Partners's ESPR Position: Q2 2026 in Review

Sivia Capital Partners sold out of Esperion Therapeutics (ESPR) in Q2 2026, closing a stake of 25,738 shares — an estimated $70.5K sold.

Sivia Capital Partners first reported a position in ESPR in Q2 2024 and held it in 7 quarters. The position peaked at $140K in Q4 2025. 192 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • Sivia Capital Partners reported no remaining Esperion Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Sivia Capital Partners sold 25,738 Esperion Therapeutics shares in Q2 2026, an estimated $70.5K.
  • Sivia Capital Partners first reported a position in Esperion Therapeutics in Q2 2024 and held it in 7 quarters.
  • Sivia Capital Partners's Esperion Therapeutics position peaked at $140K in Q4 2025.
  • 192 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Sivia Capital Partners's 13F filing for Q2 2026, filed 23 Jul 2026.